BlackRock, Inc. Increases Stake in Ligand Pharmaceuticals Inc.

BlackRock, Inc. has filed a Schedule 13G/A amendment, disclosing an increased ownership in Ligand Pharmaceuticals Inc. As of September 30, 2025, BlackRock beneficially owns 2,839,251 shares, representing 14.5% of the outstanding common stock. This marks an increase of 650,945 shares from their previous filing. The filing indicates that BlackRock has sole voting power over 2,792,360 shares and sole dispositive power over all 2,839,251 shares. The interest of iShares Core S&P Small-Cap ETF, a BlackRock subsidiary, in Ligand Pharmaceuticals exceeds five percent of the total outstanding common stock. The filing was signed by Spencer Fleming, Managing Director of BlackRock, on October 17, 2025.